Company News: Abbott and Solvay Pharmaceuticals

Share this article:
Abbott completed its $6.2 billion acquisition of Solvay Pharmaceuticals, and said it expects the acquisition to add about $2.9 billion to 2010 sales, mostly outside the US, and around $500 million to the company's annual R&D investment. “In addition to taking both Abbott and Solvay products into new and expanding markets, the acquisition enhances our R&D investment, providing Abbott with the opportunity to drive future pharmaceutical growth,” said Abbott chairman and CEO Miles White in a statement.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.